Milestone Pharmaceuticals Inc. Interest Expense Nonoperating
Milestone Pharmaceuticals Inc. (MIST) reported Interest Expense Nonoperating of $4.72 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement
us-gaap:InterestExpenseNonoperating · last filed 2026-08-12
- Milestone Pharmaceuticals Inc. interest expense nonoperating for the quarter ending 2026-06-30 was $4.72M, a 396.85% increase year-over-year.
- Milestone Pharmaceuticals Inc. interest expense nonoperating for the quarter ending 2026-03-31 was $4.13M, a 342.25% increase year-over-year.
- Milestone Pharmaceuticals Inc. interest expense nonoperating for the quarter ending 2025-12-31 was $985.00K, a 7.18% increase year-over-year.
- Milestone Pharmaceuticals Inc. interest expense nonoperating for the quarter ending 2025-09-30 was $967.00K, a 7.09% increase year-over-year.
- Milestone Pharmaceuticals Inc. interest expense nonoperating for fiscal 2025 was $3.84M, a 7.18% increase from fiscal 2024.
- Milestone Pharmaceuticals Inc. interest expense nonoperating for fiscal 2024 was $3.58M, a 40.21% increase from fiscal 2023.
- Milestone Pharmaceuticals Inc. interest expense nonoperating for fiscal 2023 was $2.55M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.72M 10-Q · filed 2026-08-12 | $8.86M 10-Q · filed 2026-08-12 | $9.85M derived: sum of 3 quarters · filed 2026-08-12 | $10.81M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $4.13M 10-Q · filed 2026-05-13 | $5.12M derived: sum of 2 quarters · filed 2026-05-13 | $6.09M derived: sum of 3 quarters · filed 2026-05-13 | $7.04M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $985.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-20 | $1.95M derived: sum of 2 quarters · filed 2026-03-20 | $2.90M derived: sum of 3 quarters · filed 2026-08-12 | $3.84M 10-K · filed 2026-03-20 |
| 2025-09-30 | $967.00K 10-Q · filed 2025-11-12 | $1.92M derived: sum of 2 quarters · filed 2026-08-12 | $2.85M 10-Q · filed 2025-11-12 | $3.77M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $951.00K 10-Q · filed 2026-08-12 | $1.89M 10-Q · filed 2026-08-12 | $2.81M derived: sum of 3 quarters · filed 2026-08-12 | $3.71M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $935.00K 10-Q · filed 2026-05-13 | $1.85M derived: sum of 2 quarters · filed 2026-05-13 | $2.76M derived: sum of 3 quarters · filed 2026-05-13 | $3.64M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $919.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-20 | $1.82M derived: sum of 2 quarters · filed 2026-03-20 | $2.71M derived: sum of 3 quarters · filed 2026-03-20 | $3.58M 10-K · filed 2026-03-20 |
| 2024-09-30 | $903.00K 10-Q · filed 2025-11-12 | $1.79M derived: sum of 2 quarters · filed 2025-11-12 | $2.66M 10-Q · filed 2025-11-12 | $3.52M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $887.00K 10-Q · filed 2025-08-12 | $1.76M 10-Q · filed 2025-08-12 | $2.62M derived: sum of 3 quarters · filed 2025-08-12 | $3.46M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $872.00K 10-Q · filed 2025-05-14 | $1.73M derived: sum of 2 quarters · filed 2025-05-14 | $2.57M derived: sum of 3 quarters · filed 2025-05-14 | $3.39M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $857.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $1.70M derived: sum of 2 quarters · filed 2025-03-13 | $2.52M derived: sum of 3 quarters · filed 2025-03-13 | $2.55M 10-K · filed 2025-03-13 |
| 2023-09-30 | $841.00K 10-Q · filed 2024-11-12 | $1.66M derived: sum of 2 quarters · filed 2024-11-12 | $1.70M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $820.00K 10-Q · filed 2024-08-08 | $856.00K 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B |